(Q33348319)

26 July 2017

1 reference

title

Inherited thrombophilias and anticoagulation in pregnancy (English)

1 reference

26 July 2017

1 reference

1 reference

Louise Bowles

1

1 reference

PubMed ID

12787539

26 July 2017

Hannah Cohen

series ordinal

2

1 reference

26 July 2017

1 June 2003

1 reference

Best Practice & Research: Clinical Obstetrics & Gynaecology

26 July 2017

1 reference

26 July 2017

17

1 reference

26 July 2017

3

1 reference

26 July 2017

471-489

1 reference

Activated protein C resistance in normal pregnancy.

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Development of resistance to activated protein C during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

World distribution of factor V Leiden

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Investigation and management of heritable thrombophilia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

The 20210 G-->A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A)

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Placental transport of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Maternal and fetal sequelae of anticoagulation during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Low-molecular-weight heparin for immediate management of thromboembolic disease in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Heparin-induced thrombocytopenia: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Direct thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

1 reference

7 January 2021

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

D-dimer concentrations during normal pregnancy, as measured by ELISA

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

The successful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous thrombosis and recurrent fetal loss

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Guidelines on oral anticoagulation: third edition

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Risk of idiopathic venous thromboembolism in users of progestagens alone

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Prenatal diagnosis in combined antithrombin and factor V gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

[Rapid physiological coagulation method in determination of fibrinogen]

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

Management of massive blood loss: a template guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6934%2803%2900012-9

7 January 2021

10.1016/S1521-6934(03)00012-9

Identifiers

DOI

1 reference

26 July 2017

1 reference

PubMed ID

12787539